I
n multiple experimental brain injury models, administration of erythropoiesis stimulating agents (ESA) has been associated with reduction of secondary neuronal damage in addition to improved neurologic outcomes. [1] [2] [3] [4] Parallel with neuroprotective effects in experimental settings, some recent clinical series have documented improved outcomes after ESA administration in patients with nontraumatic intracranial hemorrhage, schizophrenia, and progressive multiple sclerosis. [5] [6] [7] [8] [9] [10] The objective of this investigation was to examine the effects of ESA on outcomes in patients sustaining severe traumatic brain injury (sTBI).
METHODS
After approval by the Institutional Review Board, the trauma registry of the Los Angeles County ϩ University of Southern California Medical Center, an academic urban Level 1 trauma center, was reviewed to identify all adult patients (age, Ͼ16 years) from January 1, 1996 to December 31, 2007, admitted to the surgical intensive care unit (SICU) with sTBI. Severe TBI was defined by head Abbreviated Injury Scale (AIS) Ն3. Early deaths (SICU length of stay, Ͻ72 hours) were excluded from the analysis. Patient data were downloaded onto an Excel spreadsheet (Microsoft Excel 2003, Microsoft Corporation, Redmond, WA) and the data elements included age, gender, mechanism of injury, hypotension, and Glasgow Coma Scale on admission, AIS for all body regions (head, chest, abdomen, extremity), Injury Severity Score, the presence of anemia during the hospital stay, transfusion requirements, hospital, and SICU length of stay. For each sTBI patient with ESA administration (ESAϩ) within the first 30 days after hospital admission, 2 matched control patients without ESA administration (ESAϪ) were randomly selected from the pool of controls using a random number table. The matching criteria were gender, age (Յ55, Ͼ55 years), mechanism of injury (blunt versus penetrating), AIS for each body region, Injury Severity Score (Յ15, 16 -25, Ͼ25), hypotension on admission (systolic blood pressure Ͻ90, Ն90 mm Hg), Glasgow Coma Scale score on admission (Յ8, Ͼ8), and the presence of anemia during the hospital stay (hemoglobin, Ͻ10 g/dL). Each case matched control was chosen only if their SICU length of stay equaled or exceeded the time interval from admission to first dose of ESA administration. Administered ESA consisted of recombinant human erythropoietin (Procrit, Ortho Biotech Inc, Bridgewater, NJ), 100 U/kg by subcutaneous injection weekly or darbepoetin (Aranesp, Amgen Inc, Thousand Oaks, CA) 0.45 mcg/kg by subcutaneous injection weekly. The primary outcome measure was inhospital mortality. Secondary endpoints included incidence of acute respiratory distress syndrome, pneumonia, sepsis, acute renal failure, deep venous thrombosis (DVT), and pulmonary embolism (PE).
The differences between the ESAϩ and ESAϪ patients were tested for significance using the 2-sided Fisher exact test or 2 test for categorical variables and the Mann-Whitney rank-sum test for continuous variables. The odds ratio with a 95% confidence interval and the P value for its significance between the 2 groups were derived for outcomes (survival and complications). For survival analysis, Kaplan-Meier curves were constructed and compared using the logrank test. Statistical significance was set at P Ͻ 0.05. All statistical analyses were performed using the Statistical Package for Social Sciences (SPSS Windows), version 12.0 (SPSS Inc, Chicago, IL).
RESULTS
During the 12-year study period, 1651 SICU admissions met inclusion criteria. ESA was administered to 89 patients (5%). Each ESAϩ patient was matched to 2 identical ESAϪ controls which provided a total of 178 ESAϪ patients in the analysis. Table 1 delineates characteristics of the ESAϩ cases and their respective controls. There were no differences in any variables included in the analysis. No discrepancies were noted for head injury severity or in occurrence of specific types of head injury (Table 2 ).
In the majority of the patients [77 patients (87%)], ESA administration was initiated within the first 2 weeks of admission. Figure 1 compares mean hemoglobin levels between ESAϩ and ESAϪ patients during the initial 30 days of admission. A trend toward higher anemia occurrence in the ESAϩ group was noted with significant differences on hospital days 5, 10, 15, and 20. No difference in transfusion requirements between the 2 groups was observed.
There was no statistically significant discrepancy in the incidence of overall or specific complication rates (Table 3) . After exclusion of all expired patients from the morbidity and length of stay analysis, no significant differences in morbidity rates were observed. Mean SICU length of stay in the ESAϩ group and in the control group was 18.3 days versus 13.8 days, respectively (P ϭ 0.007) ( Table 4 ). The number of SICU-free days was not significantly different between groups (P ϭ 0.1). The mean hospital length of stay was more protracted in the ESAϩ group (31.8 days vs. 23.3 days; P ϭ 0.007). Overall mortality in the study population was 18.7% (n ϭ 50). ESAϩ cases experienced significantly lower in-hospital mortality compared with their ESAϪ counterparts (7.9% vs. 24.2%; OR: 0.27; 95% CI ϭ 0.12-0.62; P ϭ 0.001). Figure 2 depicts significantly diverging Kaplan-Meier curves for 30-day in-hospital mortality (log-rank test, P Ͻ 0.001).
DISCUSSION
Over the past decade, ESA has been administrated to millions of patients as an efficacious and safe treatment for renal failure associated anemia. 11 Recent work has demonstrated that the impact of ESA goes far beyond its effects on the bone marrow. 8, 12, 13 Erythropoietin (Epo) acts as a tissue protectant with anti-inflammatory, cell stabilizing, and antiapoptotic effects on multiple organ systems including renal, cardiac and neurologic systems. [13] [14] [15] Native Epo effects are mediated via a glycoprotein receptor which is found on a variety of tissues including peripheral and central neurons. 9, 16 The efficacy of recombinant human Epo as a neuroprotective agent has been demonstrated in several experimental brain injury models including animal models of stroke and traumatic intracranial hemorrhage. 3, 17 It has been observed in neuronal cell cultures that in response to hypoxia and ischemia, Epo receptor up-regulation occurs. The increase in Epo receptors results in improved resistance of neurons to toxic insults and attenuates dysfunc- tion resulting from hypoxic cellular damage. Additionally, it also acts as a neurotrophic agent promoting healing after injury. 9, 18 However, few clinical series on the use of ESA for neuroprotection have been reported, and the studies that do exist are small and limited. Nevertheless, their outcomes are promising. [5] [6] [7] 19 In a clinical trial of ischemic strokes, a reduced lesion size and improved neurologic outcome were observed when patients were treated with recombinant human Epo. 6 Recently a phase I/II trial of high-dose Epo in low birth weight infants demonstrated a strong trend toward diminished severity of intracranial hemorrhage and periventricular white matter injury. 5 In the largest prospective, randomized, placebo-controlled trial conducted to date, critically ill patients receiving epoetin alfa tended to have a lower mortality, and this effect was independent of transfusion requirements. 20 A subsequent post hoc cohort analysis of the trauma patients also confirmed a significant survival benefit. Interestingly, approximately 40% of the trauma cohort was admitted with a Glasgow Coma Scale Յ8. 21 Given the promising survival benefit among TBI patients in this study by Corwin et al, 20 in addition to the multiple clinical stroke trials and animal models of traumatic brain injury, we set out to investigate the survival benefits of ESA in sTBI. To our knowledge, this is the first study investigating the effect of ESA exclusively in patients with sTBI.
Our data reveals significantly lower in-hospital mortality in patients treated with ESA, independent of injury severity and admission variables that proved to be similar in cases and controls. Of significance, the number of patients who were hypotensive on admission, a known risk factor for detrimental outcome in patients with TBI, 22 were likewise exactly matched in cases and controls. Care was also taken in the matching process to ensure that ESAϪ patients did not expire before ESAϩ patients received treatment, to ensure any mortality benefit would not be due to bias.
ESAϩ patients demonstrated a trend toward higher anemia severity compared with the control group; despite this, a similar transfusion requirement between ESAϩ and ESAϪ was noted. The role of anemia and blood transfusions in TBI has recently been investigated in a retrospective study on 1150 TBI patients. 23 It was concluded that transfusions and anemia are significant risk factors for mortality after TBI. Despite being at higher risk for mortality due to a greater burden of anemia, ESAϩ patients experienced improved outcome. Conversely no increase in transfusion rate was noted in controls to explain their higher mortality. The results of this study are fully consistent with the efficacy of Epo observed in animal models of brain injury that cannot be explained entirely by ESA effects on the hematopoietic system alone or by avoidance of transfusions.
Mean SICU and hospital length of stay were prolonged in the ESAϩ group translating into improved in-hospital survival in ESAϩ cases. No significant difference was found when SICU-free days were compared; however, a trend toward higher SICU-free days in the ESAϩ group was noted. Likewise, in the prospective randomized trial by Corwin et al, 20 a trend towards longer ICU stay was observed in patients receiving epoetin alfa compared with the placebo administration group (8 vs. 7 days, P ϭ 0.43). These researchers reported similar significant reduction of in-hospital mortality in the subset of trauma patients.
Although not significant, a trend toward increased complications, in particular renal failure and thromboembolic events, was noted in ESAϩ cases. The increased incidence of renal failure in the ESAϩ group might be explained by the fact that anemia coupled with renal insufficiency was not uncommonly considered as an indication for ESA administration in our study cohort. Other complications noted in our study population were a nonsignificant trend towards more DVTs and PEs with ESA administration. This trend of increased in-hospital morbidity in ESAϩ cases may reflect, however, the effects of decreased mortality and prolonged SICU and hospital length of stay. Nevertheless, after excluding all deaths in an attempt to control for shorter ICU length of stay this nonsignificant trend of increased morbidity persisted, mirroring more accurately the possible effects of ESA treatment. Similar findings have been previously reported in nontrauma trials. 20 Corwin et al observed a significant increase in clinically relevant thrombotic vascular events in patients receiving ESA (16.5% vs. 11.5%; P ϭ 0.008). We do not dismiss the trend toward increased risk of thromboembolic events in our case cohort. However, the increases in DVT rates were seen in dose escalation trials, though the increased risk of DVT/PE in trauma patients was counterbalanced by the administration of low molecular weight heparin prophylaxis.
To the best of our knowledge this study is the first examining the use of ESA exclusively in sTBI patients. There are, however, several limitations to our study, the most important being the retrospective nature of data collection. The patients were not randomized to receive ESA, but were given ESA at the discretion of the attending physician due to low-grade anemia not mandating transfusion of packed red cells. We attempted to compensate for this lack of randomization by matching our controls as closely as possible to ESA cases by using 2:1 control to case matching. The second potential limitation of our study is the changing pattern of ESA administration over the study period as depicted in Table 1 . As in any long-term study spanning over a 12-year inclusion period, significant advances in critical care medicine may also have influenced subsequent outcomes. Finally, it remains unknown whether the trend toward increased complications will reach significance in a larger prospective trial, or if these risks can be ameliorated with judicious dose adjustment of the ESA or with thromboembolic prophylaxis.
In conclusion, ESA administration is associated with significant in-hospital survival benefit without an increase in morbidity in patients with severe head injury. Our results suggest the need for a large randomized controlled validation of ESA effects in sTBI patients.
